Canntab Therapeutics Limited, a leading innovator in cannabinoid and terpene blends in hard pill form, has provided an update on its successful product deliveries for Ontario and Australia, which augur well for the commercialization of the company's brand and products.
On January 7, 2022, Canntab completed its first shipment of 5 mg THC tablets to the Ontario Cannabis Store (OCS). Additionally, in early December 2021, Canntab completed its second shipment of both THC and CBD tablets to Australia.
In a statement, Canntab CEO Larry Latowsky said: "Our initial delivery to the OCS is a first for us and marks the beginning of a productive and growing relationship. Our product will be available to all Ontario Cannabis stores for purchase, in addition to being available for sale via the OCS website.”
READ: Canntab Therapeutics receives medical sales license from Health Canada for its Ontario facility
“We will support the sales and distribution of the Canntab brand with strong marketing materials and point-of-sale programs, engaging expert teams to educate all Ontario budtenders about the unique nature of Canntab's products and its patented delivery system. We are encouraged as well with our future listing of CBD products, which will ship to the OCS in early spring 2022."
Latowsky noted that the Toronto-based company’s second shipment to Australia is a signal of the "acceptance and success" of Canntab’s product in the Australian market.
“We anticipate an ongoing flow of orders from this market as our partners now have the confidence to roll our products throughout the country,” said Latowsky. “This really is the beginning of our full-scale commercialization with these shipments; our announcements of affiliate partnerships and the anticipated hard launch of our website later this month, that will permit all Canadians access to our products for ease of online purchase and direct to home delivery via www.canntab.ca."
Since receiving a Medical Sales License from Health Canada on November 11, 2021, Canntab has been focused on the commercialization of its products. The OSC initial shipment and second Australian shipment are just “two examples of what is expected to be numerous developments in the very near future,” said the company.
“Affiliates across Canada like pharmacy groups, health and wellness practitioners, sleep and pain clinics and other medical professionals will now be able to recommend, or prescribe our product and be fully compensated,” noted the company.
Canntab makes a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The firm’s hard pill cannabinoid formulations provide medical-grade solutions that include once-a-day and extended-release formulations, both providing an accurate dose and improved shelf stability.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive